TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05154929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and physical activity JITAI delivered through the myBPmyLife app
Description: A Fitbit smartwatch and home blood pressure monitor will be mailed to participants (in both the experimental and control arms). Participants in the intervention arm then will set up and utilize the myBPmyLife app. This app includes push notifications to promote increased physical activity and improve low-sodium food choices, establish goal setting for weekly step count and low sodium food choices, and deliver feedback on achieving the goals using a dashboard visualization within the mobile application.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Participants will receive the myBPmyLife app, a smartwatch, and blood pressure cuff. The myBPmyLife app will not be fully activated (as they are in the control arm). They will be provided with the option of downloading and installing a mHealth app that is publicly available. In this arm they will also perform the blood pressure monitoring, but do not receive the intervention components through the myBPmyLife app.
Study: NCT06397066

Intervention type: PROCEDURE
Intervention: White light endoscopy group
Description: White light endoscopy observe the characteristics of mucosa under white light

Intervention type: PROCEDURE
Intervention: Magnifying endoscopy group
Description: NBI+ME to observe the non atrophic area of the gastric fundus gland. The results depend on the ratio of gastric fundus gland.
Study: NCT06739512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrogram Guided Ablation
Description: Ablation using PFA. Guided by real-time electrogram characteristics from a multi-electrode catheter.
Study: NCT05924230

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RL 10ml/kg
Description: Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 1) will receive Ringer's lactate 10ml/kg before induction in the receiving area

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RL 15ml/kg
Description: Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 2) will receive Ringer's lactate 15ml/kg before induction in the receiving area
Study: NCT06094829

Intervention type: OTHER
Intervention: Oral cytobrush
Description: Oral epithelial cells will be collected during routine odontology appointments, upon documented non-opposition, via minimally invasive cytobrush sampling of the inner cheek

Intervention type: OTHER
Intervention: Oral cytobrush
Description: Oral epithelial cells will be collected during routine odontology appointments, upon documented non-opposition, via minimally invasive cytobrush sampling of the inner cheek
Study: NCT05644730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fusion closed loop glucose control system
Description: The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
Study: NCT06377995

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo technique
Description: The patient is in a supine position with a 90° knees flexion. The osteopath lies cephalad to the patient and places their hands on their shoulders.
Study: NCT05242744

Intervention type: DRUG
Intervention: [18F]FluorThanatrace
Description: Investigational radiopharmaceutical used with Positron Emission Tomography (PET/CT) imaging that may provide a non-invasive measurement of PARP-1 expression
Study: NCT06377995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm protocol
Description: The patient is in a supine position with a 90° knees flexion.To stretch the diaphragm, the osteopath stands at the head of the bed and places his hands on the lower edge of the ribcage and accompanies the lifting of the ribs during inhalation and maintains it during deep exhalation for up to 2 sets of 10 deep breaths separated by 1 minute. For the neuromuscular technique, the osteopath is positioned contralateral to the side to be treated and slides with the thumb under the lower part of the thorax, applying a force in the opposite direction.To inhibit the phrenic centre, the osteopath places one hand on the sternum in a caudal direction and the other in the projection of the phrenic centre in a cephalic direction.The participant inhales deeply and the osteopath presses in both directions during the expiratory phase for 10 respiratory cycles.
Study: NCT06227923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRO-HOME intervention
Description: Patients are transferred to the apartment inside the hospital setting and are evaluated and assessed also using technological devices
Study: NCT04478422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strengthening with vascular occlusion
Description: The muscle strengthening group with partial vascular occlusion will perform the strengthening exercises: single leg squat on 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat. The equipment for vascular occlusion will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017). If necessary, the pressure can be adjusted at intervals and after the end of the exercise, an interval of 5 minutes is suggested for blood reperfusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional muscle strengthening
Description: The conventional muscle strengthening group perform the same exercises as the intervention group: One-legged squat on a 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat, however, without restriction on blood flow.
Study: NCT04765462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic γδ T cells
Description: Phase 1:Enrolled patents will be administered allogeneic γδ T cells from 2x10\^6/kg, 1 x10\^7/kg to 5x10\^7/kg every 2-4 weeks to determine the recommended dose level.~Phase 2: Enrolled patents will be administered allogeneic γδ T cells at the recommended dose level to confirm the efficacy.~Whether or not in combination with other therapies will be determined by research physicians according to the disease status of enrolled patients.
Study: NCT05537181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899; HPM-6000UF Treatments
Description: The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
Study: NCT06740214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% standard bupivacaine only
Description: 20ml 0.5% standard bupivacaine only
Study: NCT06218524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide, 150mg/kg, Oral, Once/Day, 5/28 days
Study: NCT06015035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab and anlotinib in combination with chemotherapy
Description: Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200 mg) and chemotherapyfor three cycles. Surgical treatment was performed 4-6 weeks after the last chemotherapy cycle was completed. The primary endpoints assessed were pathological complete response (pCR) rate and safety.
Study: NCT05878015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1000mg intravenous every 6 hours on day 1 and day 2. 1000mg intravenous every 8 hours on day 3 as needed.
Study: NCT04873063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: BDP 3 mg bid (R product) BDP 6 mg qd (T product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: BDP 3 mg bid (R product) BDP 6 mg qd (T product)
Study: NCT04802655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-game based exercise - Exergame
Description: Selected Kinect compatible video games from Microsoft Xbox one will be applied in this group. Four video games will be selected for a session (each game will last 10 mins). Video games are active video games which participants have to use their body parts in order to control games.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity Based Exercise Group (AG)
Description: Task-oriented exercises to be performed in standing and sitting positions, including upper extremity and trunk, will be applied to the activity-based exercise group in addition to routine NDT training. Examples for activities; stepping and putting stickers on the wall, treading the play dough placed on a step board within one leg stance; reach-grasp activities progressively from sitting to standing, throwing and catching balls on a balance board.
Study: NCT05643677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: 4 mg PO, QD (3 weeks on, 1 week off)
Study: NCT06241482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery
Description: The technologies, processes and measures of enhanced recovery after surgery focus on the following aspects:~1. Early assessment and treatment~2. Optimized anesthetic protocol~3. Reducing surgical stress~4. Multi-modal comprehensive monitoring~5. Comprehensive diagnosis and treatment in neurosurgical intensive care~6. Intensive early rehabilitation treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy in neurocritical care.
Study: NCT05119907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously
Study: NCT06240143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: intravenous
Study: NCT06517316

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A plano cosmetic contact lenses
Description: Commercially approved colored contact lenses worn to alter or enhance the apparent color of the eye. Plano contact lenses do not contain visual correction and are worn for cosmetic purposes only.
Study: NCT06740214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.33% liposomal bupivacaine with 0.5% standard bupivacaine
Description: 10ml 1.33% liposomal bupivacaine (133mg) plus 10ml 0.5% standard bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.33% liposomal bupivacaine only
Description: 20ml 1.33% liposomal bupivacaine (266mg)
Study: NCT06739707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-18
Description: MD-18 administered subcutaneously to healthy individuals with overweight or obesity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-18
Description: MD-18 administered subcutaneously to healthy individuals with overweight or obesity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-18
Description: MD-18 administered subcutaneously to healthy individuals with overweight or obesity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-18
Description: MD-18 administered subcutaneously to healthy individuals with overweight or obesity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-18
Description: MD-18 administered subcutaneously to healthy individuals with overweight or obesity.
Study: NCT04548947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy in conjunction with a submucosal injection
Description: The cold snare polypectomy in conjunction with a submucosal injection is a procedure during which the endoscopist resects the colorectal polyps during a colonoscopy, without any electrocautery.
Study: NCT06739707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-18
Description: MD-18 administered subcutaneously to healthy individuals with overweight or obesity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-18
Description: MD-18 administered subcutaneously to healthy individuals with overweight or obesity.
Study: NCT06740188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptamine balanced antidepressants trazodone
Description: The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone
Study: NCT05227846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord-derived Mesenchymal Stem Cells
Description: Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
Study: NCT06740188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram hydrobromide combined with zolpidem
Description: the control group was given citalopram hydrobromide combined with zolpidem
Study: NCT06737783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic mobility exercises + Conventional therapy
Description: mobility exercises comprises of Cat and camel stretch (On hands and knees (supported with knee braces), alternating between arching the back up and dropping it down to stretch thoracic spine), Thoracic rotations in side lying (side lying on the side with knees bent, rotating the upper body to increase thoracic mobility alternatively), Thoracic extension at wall using body weight (Standing with back to wall, gently pushing the upper back into extension while keeping the lower back stable), half kneeling chop thrust (Kneeling on one knee (supported with knee braces), rotating the torso while keeping the pelvis stable to mobilize the thoracic spine) , Thoracic extension with a foam roller (Lying on the back with foam roller along thoracic spine, rolling gently to extend the thoracic spine in supine position). Adopt these positions with 5 secs hold and 15-20 reps will be performed for 2 sets and 10 reps per set.
Study: NCT06221644

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]SynVesT-1 PET/CT
Description: 60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent \[18F\]SynVesT-1 PET/CT for synaptic density assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]SynVesT-1 PET/CT
Description: 60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent \[18F\]SynVesT-1 PET/CT for synaptic density assessment
Study: NCT05643677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: participants will receive irinotecan, 100 mg/m2, intravenous drip, day1 and day 14 of every 4 weeks
Study: NCT06628115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerament V or G
Description: Cerament V or G implantation into forefoot or mid foot bone, and 7-10 days of oral antibiotics.
Study: NCT05493735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hcl 2% Jelly
Description: Participants in the experimental arm will undergo pessary removal and reinsertion after the application of lidocaine topical gel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Jelly
Description: Participants in the control arm will undergo pessary removal and reinsertion after the application of lubricating jelly.
Study: NCT06628258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moiz Cleansing Lotion
Description: Mode of Usage: Apply 5-10 ml of Moiz Cleansing Lotion to wet skin. Massage gently for 1-2 minutes, then rinse and pat dry.~Frequency: Twice a Day Route of Administration: Topical.
Study: NCT04807296

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TFLEP
Description: Thulium fiber laser (TFL) is a novel laser technology that delivers a pulsed laser at a more optimal wavelength and a shallower depth of tissue penetration leading to better hemostatic properties. Patients will undergo thulium fiber laser enucleation of the prostate (TFLEP) at the Centre Hospitalier de l'Université de Montréal (CHUM) as a treatment for benign prostate hyperplasia. The surgeon performing TFLEP is experienced in TFLEP procedures.~Fifty (50) patients will undergo TFLEP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: m-HoLEP
Description: The holmium: yttrium-aluminum-garnet (Ho: YAG) laser is the longest running and most studied laser used to perform this minimally invasive procedure. Holmium laser enucleation of the prostate reduces hospital stay and hemoglobin drop while improving IPSS and quality of life, as well as other positive postoperative outcomes compared to the historical gold standard, transurethral resection of the prostate (TURP). HoLEP has been found to have a better enucleation efficiency rate and may have better hemostatic properties when combined with the modulated pulsed laser energy featured associated with Moses technology (m-HoLEP). Patients will undergo m-HoLEP at the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île-de-Montréal as a treatment for benign prostate hyperplasia. The surgeon performing m-HoLEP is experienced in m-HoLEP procedures.~Fifty (50) patients will undergo m-HoLEP
Study: NCT04231006

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy
Description: High dose rate brachytherapy will be delivered to the site of recurrence within the prostate gland based on MRI and PSMA PET/CT
Study: NCT04564339

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosages (loading and maintenance) will be based on the participant's body weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosages (loading and maintenance) will be based on the participant's body weight.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Background Therapy
Description: Participants will receive background therapy consistent with the standard of care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Background Therapy
Description: Participants will receive background therapy consistent with the standard of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Therapy
Description: Participants will receive background therapy consistent with the standard of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Therapy
Description: Participants will receive background therapy consistent with the standard of care.
Study: NCT06690333

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker
Description: Transvenous pacemaker with left bundle area pacing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker
Description: Transcatheter pacemaker with MICRA AV
Study: NCT04862767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TASO-001((TGF-β2 targeting anti-sense oligonucleotide)
Description: 96 hour continuous infusion

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: SC, Bid
Study: NCT05651243

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester Supplement
Description: Oral ingestion of a ketone supplement combined with a flavoring agent and diluted in water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral ingestion of cellulose combined with a flavoring agent and diluted in water
Study: NCT05612204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy under MRI
Description: Biopsy under MRI
Study: NCT05219864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study: NCT05583162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Sport Project
Description: 2 interactive information lectures (given per class of 30 pupils), and 4 interactive workshops (given to sex-homogenous groups of 10 pupils). One per week, a total of 6 weeks with intervention.
Study: NCT05244213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5, d1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 260 mg/m2, d1 every 3 weeks
Study: NCT05834751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: 48-72 hours after chemotherapy,9 mg of PEG-rhG-CSF was injected subcutaneously for mobilization
Study: NCT05962307

Intervention type: DRUG
Intervention: Bulevirtide
Description: dose of 2 mg/day subcutaneously
Study: NCT05834751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RhG-CSF
Description: After clinical evaluation, rhG-CSF was given 10μ g/kg/d for mobilization until the stem cell collection was completed.
Study: NCT06626633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD3874
Description: CRD3874-SI is a STING agonist. CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells. In experiments on blood from humans, CRD3874 makes blood cells produce molecules responsible for anti-cancer activity. CRD3874 was tested in mice with cancers including leukemia, head and neck cancer, lung cancer, pancreatic cancer and sarcoma. In these mice, CRD3874 made tumors shrink or disappear, and some mice developed long-lasting immunity against cancer.